<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146532">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192919</url>
  </required_header>
  <id_info>
    <org_study_id>IOM TLK</org_study_id>
    <nct_id>NCT01192919</nct_id>
  </id_info>
  <brief_title>Tumour Registry Lung Cancer (TLK)</brief_title>
  <official_title>Clinical Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overview of treatment reality in patients with bronchial carcinoma requiring systemic
      treatment and being treated by office-based oncologists in Germany.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the
      treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient
      characteristics, comorbidities, tumor characteristics, biomarker testing and previous
      treatments are collected. During the course of observation data on all systemic treatments,
      radiotherapies, surgeries, and outcome are documented. Patients are followed until death or
      for a maximum of 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Documentation of actually used therapy forms in bronchial carcinoma requiring treatment</measure>
    <time_frame>3 years per patient</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2500</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with lung cancer</arm_group_label>
    <description>Patients with lung cancer requiring therapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with lung cancer requiring therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC)
             or neuroendocrine tumors receiving therapy

          -  written informed consent

          -  start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before
             informed consent

        Exclusion Criteria:

          -  patients not receiving any systemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Werner Tessen, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 7, 2016</lastchanged_date>
  <firstreceived_date>August 30, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bronchial carcinoma</keyword>
  <keyword>registry</keyword>
  <keyword>real life treatment</keyword>
  <keyword>cohort study</keyword>
  <keyword>NSCLC</keyword>
  <keyword>SCLC</keyword>
  <keyword>Germany</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
